Medivir AB (MVIRb.F) Recruits a New Head of Commercial Operations
6/14/2013 8:04:54 AM
More...
|
Medivir AB (MVIRb.F) Release: Primary Efficacy and Safety Data From Four Phase III Japanese Studies of Simeprevir Presented at The Japan Society of Hepatology
6/6/2013 9:20:46 AM
More...
|
Medivir AB (MVIRb.F) Presents at the Jefferies and Co. Global Healthcare Conference
5/31/2013 9:32:43 AM
More...
|
Medivir AB (MVIRb.F): an All-Oral Combination Phase II Study of Simeprevir and Samatasvir (IDX719) for the Treatment of Hepatitis C Virus Infection Initiated
5/30/2013 10:59:29 AM
More...
|
Medivir AB (MVIRb.F) Release: An All-Oral Combination Phase II Study of Simeprevir and Samatasvir (IDX719) for the Treatment of Hepatitis C Virus Infection Initiated
5/30/2013 9:37:22 AM
More...
|
Medivir AB (MVIRb.F) Release: Positive Results From a Phase Ia Study With MIV-711 for the Treatment of Skeletal Disorders
5/21/2013 9:29:19 AM
More...
|
Medivir AB (MVIRb.F) Release: Primary Efficacy and Safety Findings From Phase III Study of Simeprevir in Treatment-Experienced Patients Demonstrate Sustained Virologic Response
5/21/2013 9:19:22 AM
More...
|
Medivir AB (MVIRb.F): FDA Grants Priority Review to Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C
5/13/2013 11:13:51 AM
More...
|
Medivir AB (MVIRb.F) Release: FDA Grants Priority Review to Simeprevir for Combination Treatment of Genotype 1 Chronic Hepatitis C
5/13/2013 9:50:42 AM
More...
|
Resolutions at the Annual General Meeting in Medivir AB (MVIRb.F) on 6 May 2013
5/6/2013 9:40:23 AM
More...
|
|